

## Monogenic diabetes testing guidelines for NZ healthcare practitioners 2024


### What is the importance of making a genetic diagnosis?

The correct monogenic classification of diabetes has implications for treatment, clinical prognosis and cascade genetic counselling of family members and future offspring.

### Key updates of this guideline

- **Neonatal diabetes gene panel** is recommended for all those with diabetes diagnosed in the first 1 year of life (the highest yield is expected in those with diabetes less than 6 months or 9 months of life)
- **The Monogenic diabetes gene panel** (currently 41 genes) is indicated for all other tests.
  - The “glucokinase (GCK) first” option may be indicated for those in whom a GCK phenotype is most likely
  - Similarly test “HNF1B first”, “mt.3243A>G first”, OR “severe insulin resistance genes first”, may be indicated depending on the phenotype
  - If only a subset of genes are required for the initial request then only those genes will be reported on with a comment that the analysis may be expanded to the full panel upon email request to do so
- **Both panel tests cost \$688**

### Who to test:



## How to test:

- A new streamlined process of completing one electronic form as below is available by searching “monogenic diabetes” on the website below:  
<https://testguide.adhb.govt.nz/EGuide/>  
No monogenic database or other forms are required.  
Please include as many clinical details as possible, as this information is important for optimal gene variant curation
  - MODY risk calculator score is available on [www.diabetesgenes.org](http://www.diabetesgenes.org)
  - HNF1B risk score is listed below (appendix A)
- Endocrinologists and nurse practitioners within specialist diabetes services may request diabetes genetic testing
- **Cascade testing:** of family (whānau) members is important after identifying a proband with monogenic diabetes to ensure as many people benefit from the correct diagnosis as possible. Our last audit showed that only 1 in 6 probands diagnosed, generated a cascade test, when we would expect a much higher number.
  - Please ask the proband to inform their whānau about their genetic diagnosis so other related members can be referred to Genetic Health Service NZ (GHSNZ) based on the diagnosis in the whānau AND
    - Refer the proband to GHSNZ and include as much detailed information on family structure and relatedness (e.g. parents, how many children, siblings, family planning), ages of 1<sup>st</sup> degree relatives where they are located in NZ and where proband testing was done (especially if in an external lab). Generally test parents first to determine who else needs testing.
    - It may be possible for the proband’s whānau to attend the GHSNZ appointment if the proband is comfortable with this and an appointment may be offered virtually to make such attendance easier. This can be discussed with the scheduler at the time the appointment with GHSNZ is offered.
  - For GCK, family members may be triaged by a fasting glucose or HbA1c given the mild hyperglycemia is highly penetrant from birth.
  - For other monogenic diabetes subtypes
    - if a family member has diabetes, then a **diagnostic cascade genetic test** may be requested by the endocrinologist. Include the proband’s NHI and the familial variant on the request so that the laboratory can link the family members together
    - If a family member *does not have diabetes* (or other syndromic features), then a **predictive cascade genetic test** requires a referral to genetic health service for genetic counselling and such tests should only be requested by the genetic health service
- **Other referrals to Genetic Health Service NZ**
  - Genetic counselling for reproductive implications
  - Further assessment of those identified with Class 3 variants of uncertain significance which will usually require additional genetic testing and phenotyping of affected and unaffected family members in order to upgrade

the genetic testing result to a positive (likely pathogenic) or negative (likely benign) result

**Further information:**

- The use of precision diagnostics for monogenic diabetes: a systematic review and expert opinion. *Communications Medicine* 136 (2023) <https://www.nature.com/articles/s43856-023-00369-8>
- Genotype-stratified treatment for monogenic insulin resistance: a systematic review *Communications Medicine* 134 (2023) <https://www.nature.com/articles/s43856-023-00368-9>
- Systematic review of treatment of beta-cell monogenic diabetes <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197799/>
- Information for patients and health professionals on clinical care in monogenic diabetes <https://www.diabetesgenes.org>

**Appendix A: HNF1B risk score, consider testing if score  $\geq 8$**

Characteristics	Item	Value
Family history		+ 2
Antenatal renal abnormalities	Uni/bilateral abnormality by renal echography	+ 2
<i>Kidneys and urinary tract</i>		
Left kidney	Hyperechogenicity	+ 4
	Renal cysts	+ 4
	Hypoplasia	+ 2
	Multicystic and dysplastic kidney	+ 2
	Urinary tract malformation	+ 1
Right kidney	Solitary kidney	+ 1
	Hyperechogenicity	+ 4
	Renal cysts	+ 4
	Hypoplasia	+ 2
	Multicystic and dysplastic kidney	+ 2
Electrolyte or uric acid disorders	Urinary tract malformation	+ 1
	Solitary kidney	+ 1
	Low serum Mg <sup>2+</sup> (<0.7 mmol/l)	+ 2
Pathological findings	Low serum K <sup>+</sup> (<3.5 mmol/l)	+ 1
	Early-onset gout (> 30 years of age)	+ 2
	Oligomeganephronia or glomerular cysts	+ 1
Pancreas <sup>a</sup>	MODY or hypoplasia of tail and neck of the pancreas or pancreatic exocrine insufficiency	+ 4
Genital tract	Genital tract abnormality <sup>b</sup>	+ 4
Liver	Live test abnormalities of unknown origin <sup>c</sup>	+ 2